(Industry coverage of Eli Lilly's December 2025 TRIUMPH-4 topline announcement, including the 28.7% body weight loss figure on 12mg, the 2.1% placebo figure, and the schedule for remaining 2026 readouts.) Eli Lilly and Company
A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder
Aim for a mix of aerobic exercises (like walking, running, or cycling) and strength training (like weightlifting or resistance exercises)
Ashwood P, Anthony A, Torrente F, Wakefield AJ
Comparison to Other Diabetes Medications How do GLP-1 medications compare to other options for glucose control
Williams added